MARKET

MTNB

MTNB

Matinas Biopharm
AMEX
0.1988
+0.0163
+8.93%
After Hours: 0.1935 -0.0053 -2.67% 19:53 08/21 EDT
OPEN
0.1821
PREV CLOSE
0.1825
HIGH
0.2060
LOW
0.1800
VOLUME
832.85K
TURNOVER
--
52 WEEK HIGH
2.242
52 WEEK LOW
0.1780
MARKET CAP
2.92M
P/E (TTM)
-0.1819
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 2d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 2d ago
Why Webull Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Benzinga · 2d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 3d ago
Matinas BioPharma Has Received A Notice Of Allowance For A U.S. Patent Titled "ENCOCHLEATED ANTIFUNGAL COMPOUNDS FOR CENTRAL NERVOUS SYSTEM DELIVERY AND TREATMENT OF CRYPTOCOCCUS INFECTIONS".
Benzinga · 3d ago
Weekly Report: what happened at MTNB last week (0810-0814)?
Weekly Report · 5d ago
Weekly Report: what happened at MTNB last week (0803-0807)?
Weekly Report · 08/10 10:18
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 08/07 21:05
More
About MTNB
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.

Webull offers Matinas BioPharma Holdings Inc stock information, including AMEX: MTNB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTNB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MTNB stock methods without spending real money on the virtual paper trading platform.